Literature DB >> 17712814

Cannabidiol--recent advances.

Raphael Mechoulam1, Maximilian Peters, Eric Murillo-Rodriguez, Lumír O Hanus.   

Abstract

The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712814     DOI： 10.1002/cbdv.200790147

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN： 1612-1872            Impact factor:   2.408


  148 in total

1.  Cannabis--a valuable drug that deserves better treatment.

Authors:  Raphael Mechoulam
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective.

Authors:  Dragan M Svrakic; Patrick J Lustman; Ashok Mallya; Taylor Andrea Lynn; Rhonda Finney; Neda M Svrakic
Journal:  Mo Med       Date:  2012 Mar-Apr

Review 3.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

4.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

5.  Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.

Authors:  Nilufar Foadi; Martin Leuwer; Reyhan Demir; Reinhard Dengler; Vanessa Buchholz; Jeanne de la Roche; Matthias Karst; Gertrud Haeseler; Jörg Ahrens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-26       Impact factor: 3.000

6.  Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity.

Authors:  Der-zen LIU; Chieh-min HU; Chung-hsiung HUANG; Shiaw-pyng WEY; Tong-rong JAN
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

Review 7.  Cannabis use in pregnancy and early life and its consequences: animal models.

Authors:  Miriam Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

8.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

9.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

10.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.